Sigmoid Pharma Completes Phase II trial of CyCol(TM) in more than 100 ... MarketWatch (press release) CyCol(TM) is Sigmoid's proprietary formulation that delivers cyclosporine orally in its optimal form, targeted directly to the site of action in the colon, to offer potential for a new safe and effective approach to treat and manage ulcerative colitis. |
